HHT nosebleed drug shows promise in long-term follow-up study
NCT ID NCT07018401
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study follows 62 adults with hereditary hemorrhagic telangiectasia (HHT) who previously took pomalidomide in a clinical trial. Researchers want to see if the drug safely reduces nosebleed severity and the need for iron or blood transfusions over time. Participants take pomalidomide by mouth daily, and their bleeding scores, blood counts, and side effects are tracked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pomalidomide (Pomalyst), a drug taken by mouth to reduce bleeding
What this could lead to
If it works, this could point toward a treatment that reduces severe nosebleeds and the need for iron infusions or blood transfusions in people with HHT.
What could go wrong
This is a small follow-up study with no placebo group, so results may be less reliable. Pomalidomide can cause side effects like low blood cell counts and blood clots.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Johns Hopkins University
Baltimore, Maryland, 21218, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
University of California-San Diego
San Diego, California, 92093, United States
-
University of California-San Francisco
San Francisco, California, 94143, United States
-
University of Florida
Gainesville, Florida, 32610, United States
-
University of North Carolina, Chapel HIll
Chapel Hill, North Carolina, 27599, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Utah
Salt Lake City, Utah, 84112, United States